Full Text Journal Articles by
Author Elizabeth Plimack

Advertisement

Find full text journal articles






Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer.

Matthew D Galsky, Arjun V Balar, Peter C Black, Matthew T Campbell, Gail S Dykstra, Petros Grivas, Shilpa Gupta, Christoper J Hoimes, Lidia P Lopez, Joshua J Meeks, Elizabeth R Plimack, Jonathan E Rosenberg, Neal Shore, Gary D Steinberg, Ashish M Kamat,

A number of immunotherapies have been developed and adopted for the treatment of urothelial cancer (encompassing cancers arising from the bladder, urethra, or renal pelvis). For these immunotherapies to positively impact patient outcomes, optimal selection of agents and treatment scheduling, especially in conjunction with existing treatment paradigms, is paramount. Immunotherapies ... Read more >>

J Immunother Cancer (Journal for immunotherapy of cancer)
[2021, 9(7):]

Cited: 0 times

View full text PDF listing >>



Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 Trial.

Brian I Rini, Michael B Atkins, Elizabeth R Plimack, Denis Soulières, Raymond S McDermott, Jens Bedke, Sophie Tartas, Boris Alekseev, Bohuslav Melichar, Yaroslav Shparyk, Chihiro Kondoh, Przemyslaw Langiewicz, Lori A Wood, Hans Hammers, Cynthia G Silber, Barbara Haber, Erin Jensen, Mei Chen, Thomas Powles,

<h4>Background</h4>Pembrolizumab plus axitinib improved efficacy over sunitinib in treatment-naive advanced renal cell carcinoma in the KEYNOTE-426 (NCT02853331) study. However, a relatively high incidence of grade 3/4 aminotransferase elevations was observed.<h4>Objective</h4>To further characterize treatment-emergent aminotransferase elevations in patients treated with pembrolizumab-axitinib.<h4>Design, setting, and participants</h4>Patients enrolled in KEYNOTE-426 were included in this ... Read more >>

Eur Urol Oncol (European urology oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Advertisement

The European Urology Commitment to Gender Equity and Diversity: Expanding Cognitive Diversity through Inclusivity at the Podium.

Sarah P Psutka, Todd Morgan, Maarten Albersen, Jean-Nicolas Cornu, Giacomo Novara, Elizabeth Plimack, Piet Ost, James W F Catto,

Eur Urol (European urology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Systemic Therapy for Advanced Non-clear-Cell Renal Cell Carcinoma: Slow but Definite Progress.

Daniel M Geynisman, Elizabeth R Plimack,

Eur Urol (European urology)
[2021, 80(2):171-173]

Cited: 0 times

View full text PDF listing >>



Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance).

Jonathan E Rosenberg, Karla A Ballman, Susan Halabi, Pamela J Atherton, Amir Mortazavi, Christopher Sweeney, Walter M Stadler, Benjamin A Teply, Joel Picus, Scott T Tagawa, Sreedhar Katragadda, Daniel Vaena, Jamal Misleh, Christopher Hoimes, Elizabeth R Plimack, Thomas W Flaig, Robert Dreicer, Dean Bajorin, Olwen Hahn, Eric J Small, Michael J Morris,

<h4>Purpose</h4>The combination of gemcitabine and cisplatin (GC) is a standard therapy for metastatic urothelial carcinoma. Based on data that angiogenesis plays a role in urothelial carcinoma growth and progression, a randomized placebo-controlled trial was performed with the primary objective of testing whether patients treated with GC and bevacizumab (GCB) have ... Read more >>

J Clin Oncol (Journal of clinical oncology : official journal of the American Society of Clinical Oncology)
[2021, :JCO2100286]

Cited: 2 times

View full text PDF listing >>



Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis.

Toni K Choueiri, Todd M Bauer, Kyriakos P Papadopoulos, Elizabeth R Plimack, Jaime R Merchan, David F McDermott, M Dror Michaelson, Leonard J Appleman, Sanjay Thamake, Rodolfo F Perini, Naseem J Zojwalla, Eric Jonasch,

Hypoxia-inducible factor-2α (HIF-2α) is a transcription factor that frequently accumulates in clear cell renal cell carcinoma (ccRCC), resulting in constitutive activation of genes involved in carcinogenesis. Belzutifan (MK-6482, previously known as PT2977) is a potent, selective small molecule inhibitor of HIF-2α. Maximum tolerated dose, safety, pharmacokinetics, pharmacodynamics and anti-tumor activity ... Read more >>

Nat Med (Nature medicine)
[2021, 27(5):802-805]

Cited: 3 times

View full text PDF listing >>



Safety of neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer and malignant ureteric obstruction.

Marshall C Strother, Alexander Kutikov, Matthew Epstein, Emily Bochner, Mengying Deng, Elizabeth Handorf, Bianca Lewis, Pooja Ghatalia, Richard E Greenberg, David Chen, Rosalia Viterbo, Fern Anari, Marc C Smaldone, Matthew R Zibelman, Robert G Uzzo, Elizabeth R Plimack, Daniel M Geynisman,

<h4>Objectives</h4>To determine whether patients with carcinoma invading bladder muscle (MIBC) and ureteric obstruction can safely receive cisplatin-based neoadjuvant chemotherapy (C-NAC), and to determine whether such patients require relief of obstruction with a ureteric stent or percutaneous nephrostomy prior to beginning C-NAC.<h4>Patients and methods</h4>We performed a single-institution retrospective analysis of MIBC ... Read more >>

BJU Int (BJU international)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Cystoscopy and Systematic Bladder Tissue Sampling in Predicting pT0 Bladder Cancer: A Prospective Trial.

Matthew Zibelman, Aeen M Asghar, Daniel C Parker, John O'Neill, Shuanzeng Wei, Richard E Greenberg, Marc C Smaldone, David Y T Chen, Rosalia Viterbo, Robert G Uzzo, Evan Bloom, Rutika Kokate, Daniel M Geynisman, Pooja Ghatalia, Mengying Deng, Eric A Ross, Elizabeth Plimack, Philip H Abbosh, Alexander Kutikov,

<h4>Purpose</h4>Concern for discordance between clinical staging and final pathology drives current management of patients deemed appropriate candidates for radical cystectomy. Therefore, we set out to prospectively investigate reliability and shortcomings of cystoscopic evaluation in radical cystectomy candidates.<h4>Materials and methods</h4>Patients undergoing radical cystectomy for urothelial carcinoma were enrolled in a prospective ... Read more >>

J Urol (The Journal of urology)
[2021, 205(6):1605-1611]

Cited: 0 times

View full text PDF listing >>



Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: Long-term efficacy and safety from a phase Ib trial.

Michael B Atkins, Elizabeth R Plimack, Igor Puzanov, Mayer N Fishman, David F McDermott, Daniel C Cho, Ulka Vaishampayan, Saby George, Jamal C Tarazi, William Duggan, Rodolfo Perini, Mahgull Thakur, Kathrine C Fernandez, Toni K Choueiri,

<h4>Background</h4>Axitinib plus pembrolizumab showed superior overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) versus sunitinib in a randomised phase III trial in patients with advanced renal-cell carcinoma (RCC). We report long-term efficacy and safety of the axitinib/pembrolizumab from the phase I trial (NCT02133742), after 46-55 months from ... Read more >>

Eur J Cancer (European journal of cancer (Oxford, England : 1990))
[2021, 145:1-10]

Cited: 0 times

View full text PDF listing >>



Genetic Differences Between Bladder and Upper Urinary Tract Carcinoma: Implications for Therapy.

John P Sfakianos, Zeynep Gul, Shahrokh F Shariat, Surena F Matin, Siamak Daneshmand, Elizabeth Plimack, Seth Lerner, Morgan Roupret, Sumanta Pal,

<h4>Context</h4>Bladder urothelial carcinoma (BUC) and upper tract urothelial carcinoma (UTUC) have genetic differences, which may influence therapy.<h4>Objective</h4>The aim of the current review was to summarize the current genetic understanding of upper tract and BUC.<h4>Evidence acquisition</h4>PubMed, Cochrane, and Web of Science online databases were searched systematically up to February 2020, using ... Read more >>

Eur Urol Oncol (European urology oncology)
[2021, 4(2):170-179]

Cited: 1 time

View full text PDF listing >>



Identification of a Synthetic Lethal Relationship between Nucleotide Excision Repair Deficiency and Irofulven Sensitivity in Urothelial Cancer.

Judit Börcsök, Zsofia Sztupinszki, Raie Bekele, Sizhi P Gao, Miklos Diossy, Amruta S Samant, Kasia M Dillon, Viktoria Tisza, Sándor Spisák, Orsolya Rusz, Istvan Csabai, Helle Pappot, Zoë J Frazier, David J Konieczkowski, David Liu, Naresh Vasani, James A Rodrigues, David B Solit, Jean H Hoffman-Censits, Elizabeth R Plimack, Jonathan E Rosenberg, Jean-Bernard Lazaro, Mary-Ellen Taplin, Gopa Iyer, Søren Brunak, Rita Lozsa, Eliezer M Van Allen, Dávid Szüts, Kent W Mouw, Zoltan Szallasi,

<h4>Purpose</h4>Cisplatin-based chemotherapy is a first-line treatment for muscle-invasive and metastatic urothelial cancer. Approximately 10% of bladder urothelial tumors have a somatic missense mutation in the nucleotide excision repair (NER) gene, <i>ERCC2</i>, which confers increased sensitivity to cisplatin-based chemotherapy. However, a significant subset of patients is ineligible to receive cisplatin-based therapy ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2021, 27(7):2011-2022]

Cited: 1 time

View full text PDF listing >>



Treatment of Metastatic Urothelial Carcinoma After Previous Cisplatin-based Chemotherapy for Localized Disease: A Retrospective Comparison of Different Chemotherapy Regimens.

Olivia A Do, Lorin A Ferris, Sarah K Holt, Jorge D Ramos, Lauren C Harshman, Elizabeth R Plimack, Simon J Crabb, Sumanta K Pal, Ugo De Giorgi, Sylvain Ladoire, Jack Baniel, Andrea Necchi, Ulka N Vaishampayan, Aristotelis Bamias, Joaquim Bellmunt, Sandy Srinivas, Tanya B Dorff, Matt D Galsky, Evan Y Yu,

<h4>Background</h4>Optimal chemotherapy for patients who received cisplatin for localized urothelial carcinoma (UC) and develop metastatic disease is unclear. We compared the efficacy of platinum-based (PBC) versus non-platinum-based (NPBC) first-line chemotherapy for metastasis.<h4>Patients and methods</h4>Data were collected from the Retrospective International Study of Cancers of the Urothelial Tract (RISC), a database ... Read more >>

Clin Genitourin Cancer (Clinical genitourinary cancer)
[2021, 19(2):125-134]

Cited: 0 times

View full text PDF listing >>



Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial.

Laurence Albiges, Nizar M Tannir, Mauricio Burotto, David McDermott, Elizabeth R Plimack, Philippe Barthélémy, Camillo Porta, Thomas Powles, Frede Donskov, Saby George, Christian K Kollmannsberger, Howard Gurney, Marc-Oliver Grimm, Yoshihiko Tomita, Daniel Castellano, Brian I Rini, Toni K Choueiri, Shruti Shally Saggi, M Brent McHenry, Robert J Motzer,

<h4>Purpose</h4>To report updated analyses of the phase III CheckMate 214 trial with extended minimum follow-up assessing long-term outcomes with first-line nivolumab plus ipilimumab (NIVO+IPI) versus (vs) sunitinib (SUN) in patients with advanced renal cell carcinoma (aRCC).<h4>Methods</h4>Patients with aRCC with a clear cell component were stratified by International Metastatic Renal Cell ... Read more >>

ESMO Open (ESMO open)
[2020, 5(6):e001079]

Cited: 4 times

View full text PDF listing >>



Molecular Profiling of Exceptional Responders to Cancer Therapy.

Marijo Bilusic, Daniel Girardi, Yan Zhou, Kyungsuk Jung, Jianming Pei, Michael Slifker, Qingrong Chen, Daoud Meerzaman, Katherine Alpaugh, Denise Young, Douglas Flieder, Phillip Gray, Elizabeth Plimack,

<h4>Background</h4>The vast majority of metastatic cancers cannot be cured. Palliative treatment may relieve disease symptoms by stopping or slowing cancer growth and may prolong patients' lives, but almost all patients will inevitably develop disease progression after initial response. However, for reasons that are not fully understood, a very few patients ... Read more >>

Oncologist (The oncologist)
[2021, 26(3):186-195]

Cited: 0 times

View full text PDF listing >>



Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial.

Thomas Powles, Elizabeth R Plimack, Denis Soulières, Tom Waddell, Viktor Stus, Rustem Gafanov, Dmitry Nosov, Frédéric Pouliot, Bohuslav Melichar, Ihor Vynnychenko, Sergio J Azevedo, Delphine Borchiellini, Raymond S McDermott, Jens Bedke, Satoshi Tamada, Lina Yin, Mei Chen, L Rhoda Molife, Michael B Atkins, Brian I Rini,

<h4>Background</h4>The first interim analysis of the KEYNOTE-426 study showed superior efficacy of pembrolizumab plus axitinib over sunitinib monotherapy in treatment-naive, advanced renal cell carcinoma. The exploratory analysis with extended follow-up reported here aims to assess long-term efficacy and safety of pembrolizumab plus axitinib versus sunitinib monotherapy in patients with advanced ... Read more >>

Lancet Oncol (The Lancet. Oncology)
[2020, 21(12):1563-1573]

Cited: 21 times

View full text PDF listing >>



NCCN Guidelines Insights: Kidney Cancer, Version 1.2021.

Robert J Motzer, Eric Jonasch, Shawna Boyle, Maria I Carlo, Brandon Manley, Neeraj Agarwal, Ajjai Alva, Katy Beckermann, Toni K Choueiri, Brian A Costello, Ithaar H Derweesh, Arpita Desai, Saby George, John L Gore, Naomi Haas, Steven L Hancock, Christos Kyriakopoulos, Elaine T Lam, Clayton Lau, Bryan Lewis, David C Madoff, Brittany McCreery, M Dror Michaelson, Amir Mortazavi, Lakshminarayanan Nandagopal, Phillip M Pierorazio, Elizabeth R Plimack, Lee Ponsky, Sundhar Ramalingam, Brian Shuch, Zachary L Smith, Bradley Somer, Jeffrey Sosman, Mary A Dwyer, Angela D Motter,

The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for diagnostic workup, staging, and treatment of patients with renal cell carcinoma (RCC). These NCCN Guidelines Insights focus on recent updates to the guidelines, including changes to certain systemic therapy recommendations for patients with relapsed or stage IV RCC. They also ... Read more >>

J Natl Compr Canc Netw (Journal of the National Comprehensive Cancer Network : JNCCN)
[2020, 18(9):1160-1170]

Cited: 4 times

View full text PDF listing >>



Assessing Contemporary Trends in Female Speakership within Urologic Oncology.

Ruchika Talwar, Adrien Bernstein, Amanda Jones, Juanita Crook, Andrea B Apolo, Jennifer M Taylor, Lauren M Burke, Elizabeth R Plimack, Sima P Porten, Kirsten L Greene, Sarah P Psutka, Angela B Smith,

<h4>Objective</h4>To evaluate multidisciplinary female representation at urologic oncology conferences, we reviewed speakership trends at contemporary Society of Urologic Oncology (SUO) and American Society of Clinical Oncology Genitourinary Symposium (GU-ASCO) annual meetings.<h4>Methods</h4>Meeting programs from SUO and GU-ASCO from 2015 to 2019 were analyzed. Biographical information was determined by querying institutional websites ... Read more >>

Urology (Urology)
[2021, 150:41-46]

Cited: 1 time

View full text PDF listing >>



Patterns of Cancer Progression of Metastatic Hormone-sensitive Prostate Cancer in the ECOG3805 CHAARTED Trial.

Alan H Bryce, Yu Hui Chen, Glenn Liu, Michael A Carducci, David M Jarrard, Jorge A Garcia, Robert Dreicer, Maha Hussain, Mario Alfredo Eisenberger, Elizabeth R Plimack, Nicholas J Vogelzang, Robert S DiPaola, Lauren Harshman, Christopher J Sweeney,

<h4>Background</h4>ECOG3805 is a randomized trial of testosterone suppression with or without docetaxel for metastatic hormone-sensitive prostate cancer (mHSPC). Deeper prostate-specific antigen (PSA) suppression is prognostic for outcome. However, the concordance of PSA rise and radiographic progression has not been examined previously in mHSPC, whereas this has been reported in metastatic ... Read more >>

Eur Urol Oncol (European urology oncology)
[2020, 3(6):717-724]

Cited: 0 times

View full text PDF listing >>



Impact of timing of adjuvant chemotherapy following radical cystectomy for bladder cancer on patient survival.

Camilla M Grunewald, Alina Henn, Matthew D Galsky, Elizabeth R Plimack, Lauren C Harshman, Evan Y Yu, Simon J Crabb, Sumanta K Pal, Ajjai Shivaram Alva, Thomas Powles, Ugo De Giorgi, Neeraj Agarwal, Aristotelis Bamias, Sylvain Ladoire, Andrea Necchi, Ulka N Vaishampayan, Cora N Sternberg, Joaquim Bellmunt, Jack Baniel, Guenter Niegisch,

<h4>Background</h4>Trials of adjuvant chemotherapy following radical cystectomy generally require chemotherapy to start within 90 days postoperatively. However, it is unclear, whether the interval between surgery and start of adjuvant therapy (S-AC-interval) impacts the oncological outcome.<h4>Methods</h4>Using the Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC) data base, we identified ... Read more >>

Urol Oncol (Urologic oncology)
[2020, 38(12):934.e1-934.e9]

Cited: 0 times

View full text PDF listing >>



Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial.

Robert J Motzer, Bernard Escudier, Saby George, Hans J Hammers, Sandhya Srinivas, Scott S Tykodi, Jeffrey A Sosman, Elizabeth R Plimack, Giuseppe Procopio, David F McDermott, Daniel Castellano, Toni K Choueiri, Frede Donskov, Howard Gurney, Stéphane Oudard, Martin Richardet, Katriina Peltola, Ajjai S Alva, Michael Carducci, John Wagstaff, Christine Chevreau, Satoshi Fukasawa, Yoshihiko Tomita, Thomas C Gauler, Christian K Kollmannsberger, Fabio A Schutz, James Larkin, David Cella, M Brent McHenry, Shruti Shally Saggi, Nizar M Tannir,

<h4>Background</h4>CheckMate 025 has shown superior efficacy for nivolumab over everolimus in patients with advanced renal cell carcinoma (aRCC) along with improved safety and tolerability. This analysis assesses the long-term clinical benefits of nivolumab versus everolimus.<h4>Methods</h4>The randomized, open-label, phase 3 CheckMate 025 trial (NCT01668784) included patients with clear cell aRCC previously ... Read more >>

Cancer (Cancer)
[2020, 126(18):4156-4167]

Cited: 11 times

View full text PDF listing >>



Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell Carcinoma.

Jean-François Martini, Elizabeth R Plimack, Toni K Choueiri, David F McDermott, Igor Puzanov, Mayer N Fishman, Daniel C Cho, Ulka Vaishampayan, Bradley Rosbrook, Kathrine C Fernandez, Jamal C Tarazi, Saby George, Michael B Atkins,

<h4>Purpose</h4>Combined axitinib/pembrolizumab is approved for advanced renal cell carcinoma (aRCC). This exploratory analysis examined associations between angiogenic and immune-related biomarkers and outcomes following axitinib/pembrolizumab treatment.<h4>Patients and methods</h4>Prospectively defined retrospective correlative exploratory analyses tested biospecimens from 52 treatment-naïve patients receiving axitinib and pembrolizumab (starting doses 5 mg twice daily and 2 ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2020, 26(21):5598-5608]

Cited: 0 times

View full text PDF listing >>



Reply by Authors.

Daniel M Geynisman, Brian T Kadow, Brian M Shuch, Stephen A Boorjian, Surena F Matin, Edward Rampersaud, Barton N Milestone, Elizabeth R Plimack, Matthew R Zibelman, Alexander Kutikov, Marc C Smaldone, David Yt Chen, Rosalia Viterbo, Shreyas Joshi, Richard E Greenberg, Lois Malizzia, Thomas McGowan, Eric A Ross, Robert G Uzzo,

J Urol (The Journal of urology)
[2020, 204(3):536-537]

Cited: 0 times

View full text PDF listing >>



Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial.

Robert J Motzer, Bernard Escudier, David F McDermott, Osvaldo Arén Frontera, Bohuslav Melichar, Thomas Powles, Frede Donskov, Elizabeth R Plimack, Philippe Barthélémy, Hans J Hammers, Saby George, Viktor Grünwald, Camillo Porta, Victoria Neiman, Alain Ravaud, Toni K Choueiri, Brian I Rini, Pamela Salman, Christian K Kollmannsberger, Scott S Tykodi, Marc-Oliver Grimm, Howard Gurney, Raya Leibowitz-Amit, Poul F Geertsen, Asim Amin, Yoshihiko Tomita, M Brent McHenry, Shruti Shally Saggi, Nizar M Tannir,

<h4>Background</h4>The extent to which response and survival benefits with immunotherapy-based regimens persist informs optimal first-line treatment options. We provide long-term follow-up in patients with advanced renal cell carcinoma (aRCC) receiving first-line nivolumab plus ipilimumab (NIVO+IPI) versus sunitinib (SUN) in the phase 3 CheckMate 214 trial. Survival, response, and safety outcomes ... Read more >>

J Immunother Cancer (Journal for immunotherapy of cancer)
[2020, 8(2):]

Cited: 15 times

View full text PDF listing >>



Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer.

Jacqueline Vuky, Arjun V Balar, Daniel Castellano, Peter H O'Donnell, Petros Grivas, Joaquim Bellmunt, Thomas Powles, Dean Bajorin, Noah M Hahn, Mary J Savage, Xiao Fang, James Luke Godwin, Tara L Frenkl, Blanca Homet Moreno, Ronald de Wit, Elizabeth R Plimack,

<h4>Purpose</h4>The phase II single-arm KEYNOTE-052 study evaluated the efficacy and safety of first-line pembrolizumab for patients with locally advanced or metastatic cisplatin-ineligible urothelial carcinoma (UC).<h4>Patients and methods</h4>Three hundred seventy patients received pembrolizumab 200 mg intravenously every 3 weeks for up to 24 months. Positive tumor programmed death ligand 1 (PD-L1) ... Read more >>

J Clin Oncol (Journal of clinical oncology : official journal of the American Society of Clinical Oncology)
[2020, 38(23):2658-2666]

Cited: 13 times

View full text PDF listing >>



Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance Status.

Petros Grivas, Elizabeth R Plimack, Arjun V Balar, Daniel Castellano, Peter H O'Donnell, Joaquim Bellmunt, Thomas Powles, Noah M Hahn, Ronald de Wit, Dean F Bajorin, Misoo C Ellison, Tara L Frenkl, James L Godwin, Jacqueline Vuky,

<h4>Background</h4>Patients with treatment-naive advanced urothelial cancer (UC) ineligible for cisplatin-based chemotherapy are typically older and have comorbidities, representing a difficult-to-treat population.<h4>Objective</h4>To evaluate the safety and antitumor activity of first-line pembrolizumab in subgroups of cisplatin-ineligible older patients (aged ≥65 and ≥75 yr) with advanced UC in KEYNOTE-052 (NCT02335424), including those with ... Read more >>

Eur Urol Oncol (European urology oncology)
[2020, 3(3):351-359]

Cited: 3 times

View full text PDF listing >>



Advertisement

Disclaimer
1.1753 s